Figure 3.

Comparisons of functional markers between TNFR2⁺Tregs and TNFR2-Tregs in MPE. (A) Gating strategy for identifying TNFR2^hi, TNFR2^low, and TNFR2^neg in CD4⁺Foxp3⁺T cells. (B) The representative percentages of Ki-67⁺ cells in TNFR2^hiTregs, TNFR2^lowTregs, and TNFR2^negTregs were determined using FACS. (B) Summary data of Ki-67⁺ cells frequency in TNFR2^hiTregs, TNFR2^lowTregs, and TNFR2^negTregs (n=16). (D) Correlation between Ki-67 and TNFR2 expressed by Tregs in MPE (n=16). (E) The histogram showing the expression of CTLA-4 and PD-L1 on TNFR2⁺Tregs (red filled histogram) and TNFR2^-Tregs (blue filled). The gray filled histogram depicts the isotype control. (F) The graph summarizes the frequency of CTLA-4⁺ cells and PD-L1⁺ cells within each cell type (n=11). (G) TNFR2 expression correlates with CTLA-4 and PD-L1 expression on Tregs in MPE (n=11). The percentages were determined by flow cytometry. Data are expressed as means ± SEM. Flow analysis was gated on live cells. ***, P<0.001, ****, P<0.0001 by one-way ANOVA or Paired Student’s t-test. Correlations were determined by Spearman’s rank correlation coefficients. TNFR2, tumor necrosis factor receptor type II; MPE, malignant pleural effusion.